logo

For the Inventor, By the Inventor

London, United Kingdom

Atopix Therapeutics Limited


USPTO Granted Patents = 9

% Expired Patents = 44.4



Forward Citations = 28

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Mark Whittaker (3 out of 17 patents)

silverMedal Graham Michael Wynne (3 out of 14 patents)

bronzeMedal Richard Edward Armer (3 out of 11 patents)

4.  Eric Roy Pettipher (3 out of 10 patents)

5.  Julia Vile (3 out of 8 patents)

6.  Frank Schroer (3 out of 5 patents)

7.  Aimesther Betancourt (2 out of 4 patents)

8.  Katja Grosse-Sender (2 out of 2 patents)

9.  Rolf Hilfiker (2 out of 2 patents)

10.  Jacques Tonnel (2 out of 2 patents)

11.  Marc Lemieux (2 out of 2 patents)

12.  Roch Thibert (2 out of 2 patents)

13.  Sylvie Blanchet (1 out of 4 patents)

14.  Guillaume Léonard Pierre Dewaele (1 out of 1 patent)

15.  Tony Pintus (1 out of 1 patent)


9 patents:

1. 10011584 - Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid (2018-07-03),
2. 9951042 - Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl] pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid (2018-04-24),
3. 9828359 - Process for the preparation of 3-substituted (indol-1-yl)-acetic acid esters (2017-11-28),
4. 9102658 - Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters (2015-08-11),
5. 8980927 - Compounds having CRTH2 antagonist activity (2015-03-17),
6. 8980918 - Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid (2015-03-17),
7. 8703956 - Amorphous (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid (2014-04-22),
8. 8563536 - Compounds having CRTH2 antagonist activity (2013-10-22),
9. 8536158 - Compounds having CRTH2 antagonist activity (2013-09-17),
Company Overview
Atopix Therapeutics Limited is a biopharmaceutical company focusing on developing novel drugs for the treatment of allergic diseases. The company's innovative approach targets the underlying cause of allergic inflammation to provide long-lasting relief for patients. With a team of experienced researchers and clinicians, Atopix is dedicated to advancing therapeutics that improve the lives of those suffering from allergies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#348 in London

#1,902 in United Kingdom

London, GB
London, United Kingdom

Atopix Therapeutics Limited

Forward Citations = 28

16 inventors:

goldMedal Mark Whittaker (3 out of 17 patents)

silverMedal Graham Michael Wynne (3 out of 14 patents)

bronzeMedal Richard Edward Armer (3 out of 11 patents)

4.  Eric Roy Pettipher (3 out of 10 patents)

5.  Julia Vile (3 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Atopix Therapeutics Limited. Retrieved from https://idiyas.com/company/atopix-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…